Patch and Update Mechanism Testing

Published June 11, 2026

Why this matters

Section 524B has applied to covered submissions since March 29, 2023. The February 3, 2026 final guidance supersedes the June 27, 2025 final guidance and primarily aligns with the QMSR; it did not create statutory patching duties. Supporting tests should demonstrate that the proposed update mechanism works securely.

The clinical consequence is direct: vulnerabilities can accumulate over a device’s supported life. Explain the update strategy, limitations, compensating controls, and residual risks; do not infer an automatic prohibition on every device lacking an in-device patch mechanism.

Official sources: FDA, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (February 2026); FDA, Postmarket Management of Cybersecurity in Medical Devices (2016); CISA Known Exploited Vulnerabilities Catalog; FDA Cybersecurity in Medical Devices FAQs (Section 524B).

What Section 524B(b)(2) actually requires

The statute requires manufacturers to:

1. Design the device so it can be updated and patched.
2. Demonstrate the ability to update and patch in a reasonably and reliably timely manner.
3. Maintain the ability to do so across the deployed lifetime.

The Feb 2026 guidance translates that into evidence the submission must contain:

[PRACTICAL SUMMARY] Describe the update mechanism, provide evidence of secure and reliable operation, and explain postmarket patch delivery commitments. This is a summary, not a verbatim FDA quotation.

Timeliness should be justified by risk, and reliability should be supported by testing under realistic and adverse conditions. Neither term creates a universal numeric SLA.

The test cases reviewers look for

The following are example test cases to assess for the proposed update mechanism. Select and justify coverage based on architecture and risk; this list is neither a universal FDA minimum nor a guarantee of first-cycle acceptance.

Signature verification

• Apply a valid signed update, expect success.
• Apply an update with an invalid signature, expect rejection and logged event.
• Apply an update signed by a different (untrusted) key, expect rejection.
• Apply an update with a malformed signature block, expect rejection without crash.

Anti-rollback / version monotonicity

• Apply an older signed update than the currently installed version, expect rejection with logged event.
• Attempt to flash a known-vulnerable signed historical version, expect rejection.
• Verify that the rollback policy is enforced at the bootloader (not just the application).

Update channel authentication

• Spoof the update server (DNS / certificate manipulation), expect TLS validation failure and update abort.
• Replay a captured-then-modified update, expect signature failure or replay protection.
• Run the update over a network with on-path adversary tooling, confirm integrity is preserved.

Partial / interrupted updates

• Interrupt the update at multiple points (network drop, power loss, watchdog reset), expect either successful resumption or safe rollback to the prior known-good image.
• Verify the device never boots into a partially-updated state.
• Verify the device remains clinically safe during the update window (or documents the safe down-state).

Post-update integrity

• After a successful update, verify the bootloader chain still passes attestation.
• Verify logs record the update with a tamper-resistant entry.
• Verify any keys rotated as part of the update are usable and that the prior keys are revoked.

Patch delivery SLA

• Document the measured time from a representative CVE disclosure → patch availability → patch deployment.
• Provide evidence (a CAPA record, a previous patch cycle log) that this SLA has been achieved in practice, not just promised.

What an acceptable patchability evidence package looks like

A Section 524B(b)(2) evidence package that reviewers accept on first read typically contains:

See also: FDA Submission Issue Request: Cybersecurity Q-Submission Guide, Docker Containers in Medical Devices: FDA Testing, and DAST vs Penetration Testing for FDA Submissions.

• Update mechanism design description (filed in eSTAR Slot 6) with the cryptographic primitives, key management, channel design, and failure-mode handling
• Test plan mapping each of the test categories above to specific test IDs
• Test report with results for each test ID, including evidence (logs, screenshots, packet captures) for the negative cases
• SLA narrative stating the time-from-CVE-disclosure-to-deployed-patch target and the prior-cycle evidence supporting it
• Postmarket commitment referenced from the Cybersecurity Management Plan and the Vulnerability Management Plan
• Operator-facing labeling describing how the update reaches the deployed device

This evidence sits across eSTAR v7.1 Slots 1 (Management Plan), 6 (Controls), and 7 (Testing), with cross-references that let a reviewer follow the thread.

Common deficiency patterns

The four deficiency patterns we see most often on patchability:

1. Mechanism described, not tested. The submission has an update-mechanism diagram but no Slot 7 test report exercising it. Most common pattern by a wide margin.
2. No anti-rollback evidence. Devices that prevent unsigned updates but happily accept older signed-and-vulnerable versions. Reviewers ask explicitly for rollback test cases now.
3. No documented SLA. A general statement that "patches will be delivered promptly" with no measurable time target.
4. No partial-update safety analysis. Reviewers ask "What happens if power is lost at byte N of the update?" If the answer is not in the submission, it becomes an AI request.

How Blue Goat Cyber tests patch mechanisms

Our pen testers run patch mechanisms through every test case above on a calibrated bench: signature manipulation, key substitution, rollback attempts to known-vulnerable signed versions, update-server impersonation using a controlled network endpoint and untrusted certificate, repeated mid-update interruption with controlled power and network conditions, and post-update attestation. We deliver the Section 524B(b)(2) evidence package as part of the Slot 6 + Slot 7 attachments, with the traceability matrix back to the threat model.

If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed. See our penetration testing service and the related FDA Cybersecurity Testing Requirements Taxonomy.

If you want one team to own the whole cybersecurity package, see our full-service FDA premarket cybersecurity submission support.

To keep your SBOM and vulnerability records current after clearance, GoatWatch matches components to new CVEs and tracks VEX decisions.

FAQ

Ready to test your patch mechanism?

If you are preparing a 510(k), De Novo, or PMA submission and have not yet exercised the patch mechanism under negative conditions, we will scope the testing to Section 524B(b)(2) and deliver an eSTAR-ready evidence package. Request a scoping call.

Christian Espinosa, Founder, Blue Goat Cyber., ex-military red team. Has tested patch and update mechanisms across more than 275 FDA-submitted medical devices, including infusion pumps, implantables, and connected diagnostics. More on the author.

Related reading

• The SPDF Playbook
• eSTAR v7.1 Cybersecurity Attachments mapping

More on this topic

• FDA Cybersecurity Documentation
• Q-Sub vs Pre-Sub: FDA Cybersecurity Feedback Guide